



MONUMENT
THERAPEUTICS


Bringing Precision Medicine to Neuroscience Drug Development

A New Era For Neuroscience Drug Development


Brain disorders are among the greatest unmet medical needs

We are entering a new precision medicine era in neuroscience

Monument Tx has developed a unique approach
based on validated, scalable digital biomarkers
de-risking and accelerating neuroscience drug development






Applying Stratified Medicine to Improve The Odds In Neuroscience Drug Development



Monument Programs Combine Digital Biomarkers & Drugs

Our proprietary biomarkers:



- Exclusive license to use CANTAB platform
- 3000 publications and use by 8/10 top pharma
- Highly scalable: take just a few minutes

Our novel formulations of known drugs:



- Apply well-characterized drugs in novel therapeutic areas
- Optimised for efficacy
- Strong IP protection


MT1988: Cognitive Impairment Associated with Schizophrenia

Unmet Need: Cognitive Symptoms

- Affect 75% of patients with schizophrenia
- No drugs approved

Market Opportunity

- Affects ~4m patients in US and western Europe
- Estimated market potential: >\$1bn/year



Monument Tx Solution: Biomarker + Drug

- Our digital biomarker detects subgroup suitable for nicotinic treatment
- Therapeutic is a fixed-dose combination of two nicotinic agents:-

Better safety profile than either alone

Better efficacy than either alone
- Strong preclinical data demonstrates mechanistic link and pro-cognitive effect




MT1980: Neuroinflammation & Post-Operative Cognitive Decline

Unmet Need:

- 19m surgeries performed annually in over-65s in the US
- Each carries ~15% risk of developing POCD
- No drugs approved

Market Opportunity

- Drug + biomarker could prevent 1m POCD cases/year
- Long-term opportunity in unlocking major neuroinflammatory indications (e.g. Alzheimer's)




Monument Tx Solution: Biomarker + Drug

- Pre-surgical digital biomarker detects 88% increase in risk for POCD in over-65s
- MT1980 is a small molecule in a proprietary lipid formulation, with broad anti-inflammatory profile
- Strong preclinical and phase 1 data



Current & Series A-Enabled Pipeline



Leadership

Founding Team

Experts in digital biomarkers for drug development



Jenny Barnett
CEO



Kiri Granger
Chief Scientist



Sheryl Caswell
Head of Development



Mark Treherne
Chair



Julian Gilbert
Non-Exec Director



Richard Bungay
Non-Exec Director

Board

Commercially-experienced Board



Advisory Board

- Prof Ed Bullmore (immuno-psychiatry)
- Michael Sand (schizophrenia)
- Prof Trevor Robbins (psychopharmacology)

- Paula Moran (psychopharmacology)
- Robin Bannister (TRx Biosciences, ex-Sosei)
- Rob Gristwood (ex-Acacia, Chiroscience)

- Stephen Wright (ex-GW Pharma)
- Steven Powell (biotech / investment)
- Ann Hayes (ex-GSK & biotech consulting)



Business Model

- Lean virtual business model with all necessary partnerships in place for drug and biomarker utilisation
- Seeking Series A of £15m (mid 2023) to fund two lead programs through proof-of-mechanism and expand pipeline
- First ROI / potential exit expected 2025 on the basis of significant value increase from positive clinical proof-of-mechanism data

Recent deals in neuroscience

Companies	Deal
	\$100m from Amgen & \$400m raise for 8 precision psychiatry programs
	\$25m upfront + >\$1bn milestones for 1 preclinical candidate + collaboration
	\$12bn deal for 1 licensed and 5 preclinical compounds
	\$2.6bn deal for multiple candidates
	\$270m upfront + \$620m for 4 clinical stage compounds



Summary

- Precision medicine approach to de-risk and accelerate neuroscience drug development
- Areas of large unmet medical need and no available treatments
- Exclusive access to validated digital biomarkers and CNS-optimised, novel formulations
- Two clinical programs ready for proof of mechanism studies, with strong preclinical efficacy + safety data
- Series A of ~£15m in mid 2023 with first ROI / exit expected from 2025





Bringing Precision Medicine to Neuroscience Drug Development

monumenttx.com

CEO Jenny Barnett: jbarnett@monumenttx.com

Chair Mark Treherne: treherne@ntlworld.com